A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups

Primary central nervous system lymphoma (PCNSL) is a highly aggressive and rare extranodal non-Hodgkin lymphoma (NHL). The MSKCC and the IELSG scores represent the most widely used prognostic models, but many changes have occurred in therapeutic protocols since their development. Moreover, many PCNS...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology Vol. 11; p. 696147
Main Authors: Gao, Yuting, Wei, Li, Kim, Seok Jin, Wang, Liang, He, Yingzhi, Zheng, Yanfang, Bertero, Luca, Pellerino, Alessia, Cassoni, Paola, Tamagnone, Luca, Theresa, Prochazka Katharina, Deutsch, Alexander, Zhan, Huien, Lai, Jing, Wang, Yao, You, Hua
Format: Journal Article
Language:English
Published: Switzerland Frontiers Media S.A 03-08-2021
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Primary central nervous system lymphoma (PCNSL) is a highly aggressive and rare extranodal non-Hodgkin lymphoma (NHL). The MSKCC and the IELSG scores represent the most widely used prognostic models, but many changes have occurred in therapeutic protocols since their development. Moreover, many PCNSL patients cannot be classified using the IELSG score. We thus aimed to create a novel, effective and feasible prognostic model for PCNSL. We included 248 PCNSL patients diagnosed with PCNSL. Our primary endpoint was the overall survival (OS) and we used the receiver operating characteristic (ROC) analysis to determine the optimal prognostic cut-off value for LLR (lactate dehydrogenase-to-lymphocyte ratio), neutrophil-to-lymphocyte ratio (NLR) and derived neutrophil-to-lymphocyte ratio (dNLR). Variable associated with OS were evaluated by univariate and multivariate analyses. 124 out of 248 patients were randomly selected as the internal validation cohort. By univariate analysis, an age >60 years, Eastern Cooperative Oncology Group performance status (ECOG PS) >1, treatment with radiotherapy alone, high-risk groups of Memorial Sloan Kettering Cancer Center (MSKCC) score, NLR >4.74, dNLR >3.29, and LLR >166.8 were significantly associated with a worse OS. By multivariate analysis, the MSKCC score and LLR were confirmed as independent prognostic parameters for poorer OS. OS, however, was not significantly different between low- and intermediate-risk groups according to the MSKCC score, while LLR proved to be prognostically relevant and was thus used to develop a novel, effective three-tier PCNSL scoring system. Of 124 patients, 84 patients with survival data and LLR data were successfully validated by newly established PCNSL LLR scoring system. In the present study, we demonstrate that a high LLR represents an independent unfavorable prognostic parameter in PCNSL patients which can be integrated into an effective prognostic model.
AbstractList BACKGROUNDPrimary central nervous system lymphoma (PCNSL) is a highly aggressive and rare extranodal non-Hodgkin lymphoma (NHL). The MSKCC and the IELSG scores represent the most widely used prognostic models, but many changes have occurred in therapeutic protocols since their development. Moreover, many PCNSL patients cannot be classified using the IELSG score. We thus aimed to create a novel, effective and feasible prognostic model for PCNSL. METHODSWe included 248 PCNSL patients diagnosed with PCNSL. Our primary endpoint was the overall survival (OS) and we used the receiver operating characteristic (ROC) analysis to determine the optimal prognostic cut-off value for LLR (lactate dehydrogenase-to-lymphocyte ratio), neutrophil-to-lymphocyte ratio (NLR) and derived neutrophil-to-lymphocyte ratio (dNLR). Variable associated with OS were evaluated by univariate and multivariate analyses. 124 out of 248 patients were randomly selected as the internal validation cohort. RESULTSBy univariate analysis, an age >60 years, Eastern Cooperative Oncology Group performance status (ECOG PS) >1, treatment with radiotherapy alone, high-risk groups of Memorial Sloan Kettering Cancer Center (MSKCC) score, NLR >4.74, dNLR >3.29, and LLR >166.8 were significantly associated with a worse OS. By multivariate analysis, the MSKCC score and LLR were confirmed as independent prognostic parameters for poorer OS. OS, however, was not significantly different between low- and intermediate-risk groups according to the MSKCC score, while LLR proved to be prognostically relevant and was thus used to develop a novel, effective three-tier PCNSL scoring system. Of 124 patients, 84 patients with survival data and LLR data were successfully validated by newly established PCNSL LLR scoring system. CONCLUSIONSIn the present study, we demonstrate that a high LLR represents an independent unfavorable prognostic parameter in PCNSL patients which can be integrated into an effective prognostic model.
Primary central nervous system lymphoma (PCNSL) is a highly aggressive and rare extranodal non-Hodgkin lymphoma (NHL). The MSKCC and the IELSG scores represent the most widely used prognostic models, but many changes have occurred in therapeutic protocols since their development. Moreover, many PCNSL patients cannot be classified using the IELSG score. We thus aimed to create a novel, effective and feasible prognostic model for PCNSL. We included 248 PCNSL patients diagnosed with PCNSL. Our primary endpoint was the overall survival (OS) and we used the receiver operating characteristic (ROC) analysis to determine the optimal prognostic cut-off value for LLR (lactate dehydrogenase-to-lymphocyte ratio), neutrophil-to-lymphocyte ratio (NLR) and derived neutrophil-to-lymphocyte ratio (dNLR). Variable associated with OS were evaluated by univariate and multivariate analyses. 124 out of 248 patients were randomly selected as the internal validation cohort. By univariate analysis, an age >60 years, Eastern Cooperative Oncology Group performance status (ECOG PS) >1, treatment with radiotherapy alone, high-risk groups of Memorial Sloan Kettering Cancer Center (MSKCC) score, NLR >4.74, dNLR >3.29, and LLR >166.8 were significantly associated with a worse OS. By multivariate analysis, the MSKCC score and LLR were confirmed as independent prognostic parameters for poorer OS. OS, however, was not significantly different between low- and intermediate-risk groups according to the MSKCC score, while LLR proved to be prognostically relevant and was thus used to develop a novel, effective three-tier PCNSL scoring system. Of 124 patients, 84 patients with survival data and LLR data were successfully validated by newly established PCNSL LLR scoring system. In the present study, we demonstrate that a high LLR represents an independent unfavorable prognostic parameter in PCNSL patients which can be integrated into an effective prognostic model.
BackgroundPrimary central nervous system lymphoma (PCNSL) is a highly aggressive and rare extranodal non-Hodgkin lymphoma (NHL). The MSKCC and the IELSG scores represent the most widely used prognostic models, but many changes have occurred in therapeutic protocols since their development. Moreover, many PCNSL patients cannot be classified using the IELSG score. We thus aimed to create a novel, effective and feasible prognostic model for PCNSL.MethodsWe included 248 PCNSL patients diagnosed with PCNSL. Our primary endpoint was the overall survival (OS) and we used the receiver operating characteristic (ROC) analysis to determine the optimal prognostic cut-off value for LLR (lactate dehydrogenase-to-lymphocyte ratio), neutrophil-to-lymphocyte ratio (NLR) and derived neutrophil-to-lymphocyte ratio (dNLR). Variable associated with OS were evaluated by univariate and multivariate analyses. 124 out of 248 patients were randomly selected as the internal validation cohort.ResultsBy univariate analysis, an age >60 years, Eastern Cooperative Oncology Group performance status (ECOG PS) >1, treatment with radiotherapy alone, high-risk groups of Memorial Sloan Kettering Cancer Center (MSKCC) score, NLR >4.74, dNLR >3.29, and LLR >166.8 were significantly associated with a worse OS. By multivariate analysis, the MSKCC score and LLR were confirmed as independent prognostic parameters for poorer OS. OS, however, was not significantly different between low- and intermediate-risk groups according to the MSKCC score, while LLR proved to be prognostically relevant and was thus used to develop a novel, effective three-tier PCNSL scoring system. Of 124 patients, 84 patients with survival data and LLR data were successfully validated by newly established PCNSL LLR scoring system.ConclusionsIn the present study, we demonstrate that a high LLR represents an independent unfavorable prognostic parameter in PCNSL patients which can be integrated into an effective prognostic model.
Author Kim, Seok Jin
Pellerino, Alessia
Zheng, Yanfang
Bertero, Luca
Tamagnone, Luca
He, Yingzhi
Cassoni, Paola
Lai, Jing
Deutsch, Alexander
Zhan, Huien
Wang, Yao
Theresa, Prochazka Katharina
Gao, Yuting
Wang, Liang
Wei, Li
You, Hua
AuthorAffiliation 12 Department of Hematology, The First Affiliated Hospital of Jinan University , Guangzhou , China
9 Università Cattolica del Sacro Cuore, Department of Life Sciences and Public Health , Rome , Italy
1 Department of Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University , Guangzhou , China
6 Department of Oncology, ZhuJiang Hospital of Southern Medical University , Guangzhou , China
3 Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , South Korea
4 Department of Hematology, Beijing Tongren Hospital, Capital Medical University , Beijing , China
8 Department of Neuro-Oncology, University and City of Health and Science Hospital , Torino , Italy
5 Department of Hematology, ZhuJiang Hospital of Southern Medical University , Guangzhou , China
10 Fondazione Policlinico Universitario “A. Gemelli”- IRCCS , Rome , Italy
7 Pathology Unit, Department of Medical Sciences, University of Turin , Torino
AuthorAffiliation_xml – name: 1 Department of Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University , Guangzhou , China
– name: 6 Department of Oncology, ZhuJiang Hospital of Southern Medical University , Guangzhou , China
– name: 3 Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine , Seoul , South Korea
– name: 5 Department of Hematology, ZhuJiang Hospital of Southern Medical University , Guangzhou , China
– name: 12 Department of Hematology, The First Affiliated Hospital of Jinan University , Guangzhou , China
– name: 8 Department of Neuro-Oncology, University and City of Health and Science Hospital , Torino , Italy
– name: 11 Clinical Department of Hematology, Medical University of Graz , Graz , Austria
– name: 10 Fondazione Policlinico Universitario “A. Gemelli”- IRCCS , Rome , Italy
– name: 7 Pathology Unit, Department of Medical Sciences, University of Turin , Torino , Italy
– name: 4 Department of Hematology, Beijing Tongren Hospital, Capital Medical University , Beijing , China
– name: 9 Università Cattolica del Sacro Cuore, Department of Life Sciences and Public Health , Rome , Italy
– name: 2 NHC Key Laboratory of Birth Defects and Reproductive Health, Chongqing Population and Family Planning Science and Technology Research Institute , Chongqing , China
Author_xml – sequence: 1
  givenname: Yuting
  surname: Gao
  fullname: Gao, Yuting
  organization: Department of Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China
– sequence: 2
  givenname: Li
  surname: Wei
  fullname: Wei, Li
  organization: NHC Key Laboratory of Birth Defects and Reproductive Health, Chongqing Population and Family Planning Science and Technology Research Institute, Chongqing, China
– sequence: 3
  givenname: Seok Jin
  surname: Kim
  fullname: Kim, Seok Jin
  organization: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
– sequence: 4
  givenname: Liang
  surname: Wang
  fullname: Wang, Liang
  organization: Department of Hematology, Beijing Tongren Hospital, Capital Medical University, Beijing, China
– sequence: 5
  givenname: Yingzhi
  surname: He
  fullname: He, Yingzhi
  organization: Department of Hematology, ZhuJiang Hospital of Southern Medical University, Guangzhou, China
– sequence: 6
  givenname: Yanfang
  surname: Zheng
  fullname: Zheng, Yanfang
  organization: Department of Oncology, ZhuJiang Hospital of Southern Medical University, Guangzhou, China
– sequence: 7
  givenname: Luca
  surname: Bertero
  fullname: Bertero, Luca
  organization: Pathology Unit, Department of Medical Sciences, University of Turin, Torino, Italy
– sequence: 8
  givenname: Alessia
  surname: Pellerino
  fullname: Pellerino, Alessia
  organization: Department of Neuro-Oncology, University and City of Health and Science Hospital, Torino, Italy
– sequence: 9
  givenname: Paola
  surname: Cassoni
  fullname: Cassoni, Paola
  organization: Pathology Unit, Department of Medical Sciences, University of Turin, Torino, Italy
– sequence: 10
  givenname: Luca
  surname: Tamagnone
  fullname: Tamagnone, Luca
  organization: Fondazione Policlinico Universitario "A. Gemelli"- IRCCS, Rome, Italy
– sequence: 11
  givenname: Prochazka Katharina
  surname: Theresa
  fullname: Theresa, Prochazka Katharina
  organization: Clinical Department of Hematology, Medical University of Graz, Graz, Austria
– sequence: 12
  givenname: Alexander
  surname: Deutsch
  fullname: Deutsch, Alexander
  organization: Clinical Department of Hematology, Medical University of Graz, Graz, Austria
– sequence: 13
  givenname: Huien
  surname: Zhan
  fullname: Zhan, Huien
  organization: Department of Hematology, The First Affiliated Hospital of Jinan University, Guangzhou, China
– sequence: 14
  givenname: Jing
  surname: Lai
  fullname: Lai, Jing
  organization: Department of Hematology, The First Affiliated Hospital of Jinan University, Guangzhou, China
– sequence: 15
  givenname: Yao
  surname: Wang
  fullname: Wang, Yao
  organization: Department of Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China
– sequence: 16
  givenname: Hua
  surname: You
  fullname: You, Hua
  organization: Department of Oncology, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Guangzhou, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34422649$$D View this record in MEDLINE/PubMed
BookMark eNpVkk1vEzEQhleoiJbSOyfkI5cN_lrvmgNSlUKJSEvVgOBmOd5xsu2uHWynKL-LP4jDlqr1xdY7M894Ru_L4sB5B0XxmuAJY418Z70zE4opmQgpCK-fFUeUMl5Kzn4ePHofFicx3uB8RIUJZi-KQ8Y5pYLLo-LPKbr0d9Cjq-BXzsfUGXShwy0EZH3IajfosEPTywWa74bN2g_6PZprk3QCdAbrXZvrwOkIZfLlmGJ2OXatU-fRbNiEjI9okUIWbGf2skPeoqv8Apci-tGldedQWgOa-99IuxbNXIIwQNvtu1wsvkyn6LqLt-g8-O0mviqeW91HOLm_j4vvnz5-m34u51_PZ9PTeWm4oKlcEtYAtEtMWsZpxSqDma6tlFbwSi5NzVoJeSPQClszaQjlGoCZBhrGgNfsuJiN3NbrG7UZV6G87tQ_wYeV0iEvrAdVYQxMCCOYbHllRdNYQZaGWyakwabNrA8ja7Nd5sFMnjzo_gn0acR1a7Xyd6phNW6qKgPe3gOC_7WFmNTQRQN9rx34bVS0EqwmFaEkp-Ix1QQfYwD70IZgtbeO2ltH7a2jRuvkkjePv_dQ8N8o7C9AicUt
CitedBy_id crossref_primary_10_1007_s11060_023_04337_z
crossref_primary_10_1007_s10143_023_02248_1
crossref_primary_10_1007_s11060_024_04692_5
crossref_primary_10_1093_noajnl_vdad136
crossref_primary_10_1186_s43556_023_00141_3
crossref_primary_10_3389_fonc_2023_1104425
crossref_primary_10_1111_ejh_14159
crossref_primary_10_2298_MPNS22S1073V
Cites_doi 10.1038/bjc.2014.277
10.1016/S0360-3016(97)00571-3
10.1371/journal.pone.0134732
10.1159/000491988
10.1038/bjc.2013.763
10.1038/nature22079
10.1016/S0360-3016(98)00564-1
10.1016/j.ijrobp.2003.11.001
10.1038/oncsis.2014.16
10.1002/brb3.928
10.1016/S1470-2045(14)70263-3
10.18632/oncotarget.20480
10.1200/JCO.2003.03.108
10.1016/j.ejca.2016.01.016
10.1007/s12253-019-00707-z
10.1200/JCO.2003.09.139
10.1007/s11899-014-0217-2
10.1200/JCO.1999.17.4.1244
10.5301/tj.5000694
10.1080/14737140.2019.1677157
10.1159/000487288
10.1200/JCO.2006.08.2941
10.1002/cam4.2872
10.1016/j.ygyno.2006.05.043
10.1200/JCO.2002.11.013
10.1200/JCO.2003.11.036
10.3389/fimmu.2016.00052
10.18632/oncotarget.16720
10.1200/JCO.1998.16.3.859
10.18632/oncotarget.25306
10.1007/s00277-014-2115-z
10.1186/s12885-016-2397-8
10.1038/nature01322
ContentType Journal Article
Copyright Copyright © 2021 Gao, Wei, Kim, Wang, He, Zheng, Bertero, Pellerino, Cassoni, Tamagnone, Theresa, Deutsch, Zhan, Lai, Wang and You.
Copyright © 2021 Gao, Wei, Kim, Wang, He, Zheng, Bertero, Pellerino, Cassoni, Tamagnone, Theresa, Deutsch, Zhan, Lai, Wang and You 2021 Gao, Wei, Kim, Wang, He, Zheng, Bertero, Pellerino, Cassoni, Tamagnone, Theresa, Deutsch, Zhan, Lai, Wang and You
Copyright_xml – notice: Copyright © 2021 Gao, Wei, Kim, Wang, He, Zheng, Bertero, Pellerino, Cassoni, Tamagnone, Theresa, Deutsch, Zhan, Lai, Wang and You.
– notice: Copyright © 2021 Gao, Wei, Kim, Wang, He, Zheng, Bertero, Pellerino, Cassoni, Tamagnone, Theresa, Deutsch, Zhan, Lai, Wang and You 2021 Gao, Wei, Kim, Wang, He, Zheng, Bertero, Pellerino, Cassoni, Tamagnone, Theresa, Deutsch, Zhan, Lai, Wang and You
DBID NPM
AAYXX
CITATION
7X8
5PM
DOA
DOI 10.3389/fonc.2021.696147
DatabaseName PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
PubMed

Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: http://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2234-943X
EndPage 696147
ExternalDocumentID oai_doaj_org_article_500e366c639d45f688f61bc4f369c0cd
10_3389_fonc_2021_696147
34422649
Genre Journal Article
GrantInformation_xml – fundername: National Natural Science Foundation of China
  grantid: 81911530169, 81903088, 81670180
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
DIK
EBS
EJD
EMOBN
GROUPED_DOAJ
GX1
HYE
IAO
IEA
IHR
IHW
IPNFZ
KQ8
M48
M~E
NPM
OK1
PGMZT
RIG
RNS
RPM
AAYXX
CITATION
7X8
5PM
ID FETCH-LOGICAL-c462t-b138eedb01d342535c03a7f99f6459bc73d9e501ed6f739c124aee3c8e833e473
IEDL.DBID RPM
ISSN 2234-943X
IngestDate Tue Oct 22 15:11:50 EDT 2024
Tue Sep 17 21:28:36 EDT 2024
Fri Oct 25 01:52:00 EDT 2024
Thu Nov 21 21:22:28 EST 2024
Sat Sep 28 08:23:54 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords Memorial Sloan Kettering Cancer Center (MSKCC) score
neutrophil-to-lymphocyte ratio
lactate dehydrogenase-to-lymphocyte ratio
prognostic parameter
primary central nervous system lymphoma
Language English
License Copyright © 2021 Gao, Wei, Kim, Wang, He, Zheng, Bertero, Pellerino, Cassoni, Tamagnone, Theresa, Deutsch, Zhan, Lai, Wang and You.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c462t-b138eedb01d342535c03a7f99f6459bc73d9e501ed6f739c124aee3c8e833e473
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Reviewed by: Chan-Sik Park, University of Ulsan, South Korea; Albrecht Reichle, University Medical Center Regensburg, Germany
Edited by: Liren Qian, Fifth Medical Center of the PLA General Hospital, China
These authors have contributed equally to this work
This article was submitted to Hematologic Malignancies, a section of the journal Frontiers in Oncology
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370855/
PMID 34422649
PQID 2563715121
PQPubID 23479
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_500e366c639d45f688f61bc4f369c0cd
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8370855
proquest_miscellaneous_2563715121
crossref_primary_10_3389_fonc_2021_696147
pubmed_primary_34422649
PublicationCentury 2000
PublicationDate 2021-08-03
PublicationDateYYYYMMDD 2021-08-03
PublicationDate_xml – month: 08
  year: 2021
  text: 2021-08-03
  day: 03
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in oncology
PublicationTitleAlternate Front Oncol
PublicationYear 2021
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Romero-Garcia (B20) 2016; 7
Jahr (B31) 2018; 8
Keane (B18) 2018; 9
Dai (B16) 2017; 8
Go (B12) 2018; 104
Cheson (B19) 1999; 17
Bessell (B32) 2004; 59
Poortmans (B5) 2003; 21
Abrey (B4) 1998; 16
Jung (B28) 2017; 8
Huang (B15) 2017; 545
Hoang-Xuan (B30) 2003; 21
DeAngelis (B3) 2002; 20
Kim (B8) 2016; 16
Ji (B14) 2018; 45
Corry (B26) 1998; 41
Diakos (B25) 2014; 15
Hayabuchi (B27) 1999; 44
Troppan (B9) 2014; 111
Jang (B11) 2016; 57
Seidel (B2) 2019; 19
Phillips (B1) 2014; 9
Coussens (B10) 2002; 420
Abrey (B7) 2006; 24
Liu (B33) 2020; 9
Ferreri (B6) 2003; 21
Li (B17) 2020; 26
Passardi (B21) 2015; 10
Troppan (B13) 2014; 110
Park (B24) 2014; 93
Giatromanolaki (B22) 2006; 103
Allison (B23) 2014; 3
Uz (B29) 2018; 140
References_xml – volume: 111
  start-page: 55
  year: 2014
  ident: B9
  article-title: C-Reactive Protein Level Is a Prognostic Indicator for Survival and Improves the Predictive Ability of the R-IPI Score in Diffuse Large B-Cell Lymphoma Patients
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2014.277
  contributor:
    fullname: Troppan
– volume: 41
  year: 1998
  ident: B26
  article-title: Primary Central Nervous System Lymphoma: Age and Performance Status Are More Important Than Treatment Modality
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/S0360-3016(97)00571-3
  contributor:
    fullname: Corry
– volume: 10
  start-page: e0134732
  year: 2015
  ident: B21
  article-title: Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients With Metastatic Colorectal Cancer
  publication-title: PloS One
  doi: 10.1371/journal.pone.0134732
  contributor:
    fullname: Passardi
– volume: 140
  year: 2018
  ident: B29
  article-title: The Prognostic Value of the Derived Neutrophil-to-Lymphocyte Ratio in Transplantation-Ineligible Patients With Multiple Myeloma
  publication-title: Acta Haematol
  doi: 10.1159/000491988
  contributor:
    fullname: Uz
– volume: 110
  year: 2014
  ident: B13
  article-title: The Derived Neutrophil to Lymphocyte Ratio Is an Independent Prognostic Factor in Patients With Diffuse Large B-Cell Lymphoma
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2013.763
  contributor:
    fullname: Troppan
– volume: 545
  year: 2017
  ident: B15
  article-title: T-Cell Invigoration to Tumour Burden Ratio Associated With Anti-PD-1 Response
  publication-title: Nature
  doi: 10.1038/nature22079
  contributor:
    fullname: Huang
– volume: 44
  year: 1999
  ident: B27
  article-title: Primary Central Nervous System Lymphoma in Japan: A Nationwide Survey
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/S0360-3016(98)00564-1
  contributor:
    fullname: Hayabuchi
– volume: 59
  year: 2004
  ident: B32
  article-title: Primary Non-Hodgkin’s Lymphoma of the CNS Treated With CHOD/BVAM or BVAM Chemotherapy Before Radiotherapy: Long-Term Survival and Prognostic Factors
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2003.11.001
  contributor:
    fullname: Bessell
– volume: 3
  start-page: e102
  year: 2014
  ident: B23
  article-title: Identification of LDH-A as a Therapeutic Target for Cancer Cell Killing Via (I) p53/NAD(H)-Dependent and (Ii) p53-independent Pathways
  publication-title: Oncogenesis
  doi: 10.1038/oncsis.2014.16
  contributor:
    fullname: Allison
– volume: 8
  start-page: e00928
  year: 2018
  ident: B31
  article-title: Evaluation of Memorial Sloan-Kettering Cancer Center and International Extranodal Lymphoma Study Group Prognostic Scoring Systems to Predict Overall Survival in Intracranial Primary CNS Lymphoma
  publication-title: Brain Behav
  doi: 10.1002/brb3.928
  contributor:
    fullname: Jahr
– volume: 15
  year: 2014
  ident: B25
  article-title: Cancer-Related Inflammation and Treatment Effectiveness
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(14)70263-3
  contributor:
    fullname: Diakos
– volume: 8
  year: 2017
  ident: B28
  article-title: Prognostic Role of the Neutrophil-to-Lymphocyte Ratio in Patients With Primary Central Nervous System Lymphoma
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.20480
  contributor:
    fullname: Jung
– volume: 21
  year: 2003
  ident: B5
  article-title: High-Dose Methotrexate-Based Chemotherapy Followed by Consolidating Radiotherapy in Non-AIDS-Related Primary Central Nervous System Lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962
  publication-title: J Clin Oncol: Off J Am Soc Clin Oncol
  doi: 10.1200/JCO.2003.03.108
  contributor:
    fullname: Poortmans
– volume: 57
  year: 2016
  ident: B11
  article-title: A New Prognostic Model Using Absolute Lymphocyte Count in Patients With Primary Central Nervous System Lymphoma
  publication-title: Eur J Cancer (Oxford England: 1990)
  doi: 10.1016/j.ejca.2016.01.016
  contributor:
    fullname: Jang
– volume: 26
  year: 2020
  ident: B17
  article-title: Lactate Dehydrogenase-to-Lymphocyte Ratio Represents a Powerful Prognostic Tool of Metastatic Renal Cell Carcinoma Patients Treated With Tyrosine Kinase Inhibitors
  publication-title: Pathol Oncol Research: POR
  doi: 10.1007/s12253-019-00707-z
  contributor:
    fullname: Li
– volume: 21
  year: 2003
  ident: B6
  article-title: Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience
  publication-title: J Clin Oncol: Off J Am Soc Clin Oncol
  doi: 10.1200/JCO.2003.09.139
  contributor:
    fullname: Ferreri
– volume: 9
  year: 2014
  ident: B1
  article-title: Primary CNS Lymphoma
  publication-title: Curr Hematol Malignancy Rep
  doi: 10.1007/s11899-014-0217-2
  contributor:
    fullname: Phillips
– volume: 17
  start-page: 1244
  year: 1999
  ident: B19
  article-title: Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin’s Lymphomas. NCI Sponsored International Working Group
  publication-title: J Clin Oncol: Off J Am Soc Clin Oncol
  doi: 10.1200/JCO.1999.17.4.1244
  contributor:
    fullname: Cheson
– volume: 104
  year: 2018
  ident: B12
  article-title: A New Prognostic Model Using the NCCN-IPI and Neutrophil-to-Lymphocyte Ratio in Diffuse Large B-Cell Lymphoma
  publication-title: Tumori
  doi: 10.5301/tj.5000694
  contributor:
    fullname: Go
– volume: 19
  year: 2019
  ident: B2
  article-title: Have Treatment Protocols for Primary CNS Lymphoma Advanced in the Past 10 Years
  publication-title: Expert Rev Anticancer Ther
  doi: 10.1080/14737140.2019.1677157
  contributor:
    fullname: Seidel
– volume: 45
  year: 2018
  ident: B14
  article-title: Ratio of Immune Response to Tumor Burden Predicts Survival Via Regulating Functions of Lymphocytes and Monocytes in Diffuse Large B-Cell Lymphoma
  publication-title: Cell Physiol Biochem: Int J Exp Cell Physiol Biochem Pharmacol
  doi: 10.1159/000487288
  contributor:
    fullname: Ji
– volume: 24
  year: 2006
  ident: B7
  article-title: Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model
  publication-title: J Clin Oncol: Off J Am Soc Clin Oncol
  doi: 10.1200/JCO.2006.08.2941
  contributor:
    fullname: Abrey
– volume: 9
  year: 2020
  ident: B33
  article-title: A New Prognostic Score for Disease Progression and Mortality in Patients With Newly Diagnosed Primary CNS Lymphoma
  publication-title: Cancer Med
  doi: 10.1002/cam4.2872
  contributor:
    fullname: Liu
– volume: 103
  year: 2006
  ident: B22
  article-title: Lactate Dehydrogenase 5 (LDH-5) Expression in Endometrial Cancer Relates to the Activated VEGF/VEGFR2(KDR) Pathway and Prognosis
  publication-title: Gynecol Oncol
  doi: 10.1016/j.ygyno.2006.05.043
  contributor:
    fullname: Giatromanolaki
– volume: 20
  year: 2002
  ident: B3
  article-title: Combination Chemotherapy and Radiotherapy for Primary Central Nervous System Lymphoma: Radiation Therapy Oncology Group Study 93-10
  publication-title: J Clin Oncol: Off J Am Soc Clin Oncol
  doi: 10.1200/JCO.2002.11.013
  contributor:
    fullname: DeAngelis
– volume: 21
  year: 2003
  ident: B30
  article-title: Chemotherapy Alone as Initial Treatment for Primary CNS Lymphoma in Patients Older Than 60 Years: A Multicenter Phase II Study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group
  publication-title: J Clin Oncol: Off J Am Soc Clin Oncol
  doi: 10.1200/JCO.2003.11.036
  contributor:
    fullname: Hoang-Xuan
– volume: 7
  year: 2016
  ident: B20
  article-title: Lactate Contribution to the Tumor Microenvironment: Mechanisms, Effects on Immune Cells and Therapeutic Relevance
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2016.00052
  contributor:
    fullname: Romero-Garcia
– volume: 8
  year: 2017
  ident: B16
  article-title: Development of New Prognostic Model Based on Pretreatment βlri and LLRI for Stage IE/IIE Upper Aerodigestive Tract ENKTL, Nasal Type
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.16720
  contributor:
    fullname: Dai
– volume: 16
  year: 1998
  ident: B4
  article-title: Long-Term Survival in Primary CNS Lymphoma
  publication-title: J Clin Oncol: Off J Am Soc Clin Oncol
  doi: 10.1200/JCO.1998.16.3.859
  contributor:
    fullname: Abrey
– volume: 9
  year: 2018
  ident: B18
  article-title: A High LDH to Absolute Lymphocyte Count Ratio in Patients With DLBCL Predicts for a Poor Intratumoral Immune Response and Inferior Survival
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.25306
  contributor:
    fullname: Keane
– volume: 93
  year: 2014
  ident: B24
  article-title: The Highest Prognostic Impact of LDH Among International Prognostic Indices (Ipis): An Explorative Study of Five IPI Factors Among Patients With DLBCL in the Era of Rituximab
  publication-title: Ann Hematol
  doi: 10.1007/s00277-014-2115-z
  contributor:
    fullname: Park
– volume: 16
  start-page: 363
  year: 2016
  ident: B8
  article-title: MYC and BCL2 Overexpression Is Associated With a Higher Class of Memorial Sloan-Kettering Cancer Center Prognostic Model and Poor Clinical Outcome in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
  publication-title: BMC Cancer
  doi: 10.1186/s12885-016-2397-8
  contributor:
    fullname: Kim
– volume: 420
  year: 2002
  ident: B10
  article-title: Inflammation and Cancer
  publication-title: Nature
  doi: 10.1038/nature01322
  contributor:
    fullname: Coussens
SSID ssj0000650103
Score 2.3667855
Snippet Primary central nervous system lymphoma (PCNSL) is a highly aggressive and rare extranodal non-Hodgkin lymphoma (NHL). The MSKCC and the IELSG scores represent...
BACKGROUNDPrimary central nervous system lymphoma (PCNSL) is a highly aggressive and rare extranodal non-Hodgkin lymphoma (NHL). The MSKCC and the IELSG scores...
BackgroundPrimary central nervous system lymphoma (PCNSL) is a highly aggressive and rare extranodal non-Hodgkin lymphoma (NHL). The MSKCC and the IELSG scores...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 696147
SubjectTerms lactate dehydrogenase-to-lymphocyte ratio
Memorial Sloan Kettering Cancer Center (MSKCC) score
neutrophil-to-lymphocyte ratio
Oncology
primary central nervous system lymphoma
prognostic parameter
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagB8QF8Sa8NEhcOITGcRLH3Mq2VSW2q6oLglvk-KFdFRK02W21v4s_yIy9XXUREheusZNY_saez_b4G8beWqQEPitcis5MpIXKTdrqzKdce8EtEv4i5AY8mcrJt_rwiGRytqm-KCYsygPHjtsvs8yJqjLoSW1R-qqufcVbU3hRKZMZG2bfrLqxmIpzcEkJDOK5JK7C1L7vO1IszPn7SqFLkjt-KMj1_41j_hkqecP3HN9n9zakEQ5iYx-wW657yO6cbo7FH7FfBzDpL913OFv0FDiH1YAu4bgFICfFp0FRAkaTKYzXCF__Q3-AsTZENOHQzdYW33MdOrR02aexillj2TnhBnHjwQ0QpGwptijACb2HsyjLOsDX-XI27wDpJIz7K9CdhbDZGG6m4JdOp59GIzifDxcQtruGx-zL8dHn0Um6ycaQmqLKl2nLRY0Otc24FTjQRWkyoaVXypMeTWuksMphrztbeSmUQeKgnROmdrUQrpDiCdvr-s49Y-BxUihbwy3Sm6K0CKf0XOksb3OvZZsn7N01Ns3P2EUNLlYIx4ZwbAjHJuKYsI8E3rYeyWWHB2hEzcaImn8ZUcLeXEPf4PCiMxPduX41NMgIhSRWxBP2NJrC9leiCNeQVcLkjpHstGW3pJvPgoQ3SQ7VZfn8fzT-BbtL_RGiEsVLtrdcrNwrdnuwq9dhUPwGsI4UHQ
  priority: 102
  providerName: Directory of Open Access Journals
Title A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups
URI https://www.ncbi.nlm.nih.gov/pubmed/34422649
https://search.proquest.com/docview/2563715121
https://pubmed.ncbi.nlm.nih.gov/PMC8370855
https://doaj.org/article/500e366c639d45f688f61bc4f369c0cd
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LjtMwFLXoLBAbxJvwGF0kNizSJnFeZjdkZjQSbVVNQbCLHD-mEdN41LSgfhc_yLWTjKaIFVs_4sjn2vfYvj4m5L1ESqCDWPnozKgfs0j4FQ-0H3JNQ4mEP3ZvA14ss_n3_PTMyuQkw10YF7QvqnrcXK_HTb1ysZU3azEZ4sQmi1lhBVvyJJmMyAi54Z0lejf9Jvbtgu5IEhdgbKJNY8UKo3CcMvRG9t09GrsbpOzAGznR_n8xzb8DJu94oPNH5GFPHeGk-8XH5J5qnpD7s_5w_Cn5fQJz81Ndw2JjbPgcFgN7FUdtAJkppjpdCSjmS5juEUSz5h9hyoWlm3CqVnuJ9VSDbs3fGr8rIvaYd2nRg277QbXgBG1thJEDFYyGRSfO2sK3eruqG0BSCVPzC3gjwW05uvsp-KXZ8nNRwGXd_gC36dU-I1_Pz74UF37_JoMv4jTa-lVIc3SrVRBKisOdJiKgPNOMaatKU4mMSqYQACVTnVEmkD5wpajIVU6pijP6nBw1plEvCWicGpJKhBJJTpzIECvrkPEgqiLNsyryyIcBm_Km66ISlywW0tJCWlpIyw5Sj3yy4N2Ws6LZLsFsrsredMokCBRNU4GkTMaJTvNcp9hqrGnKRCCkR94N0Jc4yOzJCW-U2bUl8kKaWW4UeuRFZwq3TQ2m5JHswEgO_uUwB-3aCXn3dvzqv2u-Jg9sJ7iARPqGHG03O_WWjFq5O3abC8duaPwBbc0Vxg
link.rule.ids 230,315,729,782,786,866,887,2106,27933,27934,53800,53802
linkProvider National Library of Medicine
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbYkIAX7rBwPUi88JA2iXMzbyPbVLS0qtYheIsSX2i11ZmaFtTfxR_k2EmmFfG0V1_iyOezz2f7-DMhHwVSAuWF0kVnRt2QBdytSk-5fqmoL5Dwh_ZtwNEsmfxIj46NTE7U34WxQfu8Wgz05XKgF3MbW3m15MM-Tmw4HWdGsCWNouEeuYvj1fNuLNLbCTgyrxe0h5K4BGNDVWsjVxj4g5ihPzIv79HQ3iFlO_7Iyvb_j2v-GzJ5wwedPLrl3z8mDzvSCYdt9hNyR-qn5N64O1Z_Rv4cwqT-JS9huqpN4B0WA3OJR64AOS2mWkUKyCYzyLdo_npZfoa85IaowpGcbwXWkxodoruu3bYI32LembE7tBsXsgErhWtikywcoFYwbWVdG_i-WM8XGpCOQl7_hlILsJuV9mYLfmk8O80yOFs0F2C3y5rn5NvJ8Xk2crvXHFwexsHarXyaokOuPF9QnChoxD1aJooxZfRsKp5QwSQaTopYJZRxJB6llJSnMqVUhgl9QfZ1reUBAYWTSlRxXyA9CiPhY2Xls9ILqkCVSRU45FNv0-Kq7aICFzsGCoWBQmGgULRQcMgXY_TrckZu2ybUq59FZ7Yi8jxJ45gjnRNhpOI0VTG2GioaM-5x4ZAPPWQKHJ7mzKXUst40BTJKmhhW5TvkZQuh66Z6CDok2QHXzr_s5iCmrAR4h6FXt675ntwfnY_zIv86OX1NHpgOsWGN9A3ZX6828i3Za8TmnR1YfwFbFipd
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwELbYRVpx4c0SnoPEhUPaJM7L3JZ0q0XbVtUWBLco8YNGbJ2qaUH9XfxBxk5abREnuCZ2Hp7Pns_2-BtC3gqkBMoLpYvOjLohC7hbFp5y_UJRXyDhD21uwItZMvmaDs6NTM4-1ZcN2udl1dPXi56u5ja2crng_V2cWH86zoxgSxpF_aVQ_SNyG_usF9yYqLeDcGQyGLQbkzgNY31VayNZGPi9mKFPMtn3aGjPkbIDn2Sl-__GN_8Mm7zhh4b3_uMP7pO7HfmEs7bIA3JL6ofkZNxtrz8iv85gUv-Q1zBd1SYAD4uBOcwjV4DcFq9aZQrIJjMYbREG9aJ4D6OCG8IKAznfCqwnNTpGd127bRG-xXtXxv7QLmDIBqwkrolRsrCAWsG0lXdt4Eu1nlcakJbCqP4JhRZgFy3tCRd80nh2mWVwVTXfwS6bNY_J5-H5p-zC7bI6uDyMg7Vb-jRFx1x6vqA4YNCIe7RIFGPK6NqUPKGCSTSeFLFKKONIQAopKU9lSqkME_qEHOtay6cEFA4uUcl9gTQpjISPlZXPCi8oA1UkZeCQdzu75su2iXKc9Bg45AYOuYFD3sLBIR-M4ffljOy2vVCvvuWd6fLI8ySNY460ToSRitNUxfjWUNGYcY8Lh7zZwSbHbmr2Xgot602TI7OkiWFXvkNOWxjtX7WDoUOSA4AdfMvhHcSVlQLvcPTsn2u-JifTwTAffZxcPid3THvY6Eb6ghyvVxv5khw1YvPK9q3fl0Ys3Q
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Novel+Prognostic+Marker+for+Primary+CNS+Lymphoma%3A+Lactate+Dehydrogenase-to-Lymphocyte+Ratio+Improves+Stratification+of+Patients+Within+the+Low+and+Intermediate+MSKCC+Risk+Groups&rft.jtitle=Frontiers+in+oncology&rft.au=Gao%2C+Yuting&rft.au=Wei%2C+Li&rft.au=Kim%2C+Seok+Jin&rft.au=Wang%2C+Liang&rft.date=2021-08-03&rft.issn=2234-943X&rft.eissn=2234-943X&rft.volume=11&rft.spage=696147&rft.epage=696147&rft_id=info:doi/10.3389%2Ffonc.2021.696147&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2234-943X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2234-943X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2234-943X&client=summon